Present the product profiles of new drugs to doctors treating patients whose cancers have tested positive for EGFR gene mutation, and predict the differences in their inclination to prescribe the new drugs compared to existing therapeutic drugs.
By combining the product profiles of the new drugs and existing therapeutic drugs on the conjoint card, and calculating the effect size for each attribute, we can ascertain the differences in doctors’ intention to prescribe existing therapeutic drugs and new drugs.
POINT
Collecting pharmacists’ views on biosimilars, which are a key part of pharmaceutical companies’ future product strategies, and predicting their future potential
Utilizing 40,000 pharmacist panels, including pharmacists based in hospitals, in facilities, or adjoining hospitals and clinics, we can find the most suitable respondents and survey to them.
POINT
Highlight the key details for communicating the product message effectively
We conduct interview surveys with doctors to test the product message and promotional materials, and ascertain their expectations and concerns regarding the new product. This can provide insights for creating key messages and promotional materials that maximize product value.
POINT